- Active Substance: Prohibitin-targeting peptide 1
- Concentration: 2 mg
- Pack Size: vial
- Manufacturer: Ultima Pharmaceuticals
- Brand Name: Adipotide
SKU: P280
Shipping From
Understanding Ultima-Adiptode (Prohibitin-targeting peptide 1) 2mg for Adipose Tissue Research
Ultima-Adiptode, also known as Prohibitin-targeting peptide 1 (or often abbreviated as FTPP), offered by Ultima Pharmaceuticals, contains 2mg per vial. Adipotide is a synthetic peptide that is being investigated in research settings for its unique mechanism of action targeting blood vessels supplying adipose (fat) tissue.
Mechanism of Action
Adipotide is designed to selectively target cells expressing prohibitin on their surface, which are found in the vasculature of white adipose tissue. Upon binding, the peptide is believed to trigger a cascade of events leading to the apoptosis (programmed cell death) of these blood vessel cells. This targeted action aims to reduce the blood supply to fat tissue, potentially leading to its regression and a reduction in overall body fat mass.
Potential Research Benefits
- Investigated for its potential to reduce white adipose tissue mass.
- Studied for its effects on body weight and metabolic parameters in preclinical models.
- Research into its potential as a targeted therapeutic agent for obesity-related conditions.
Please note: The potential benefits listed above are based on preclinical research and have not been established in humans for therapeutic use. Adipotide is not approved for human therapeutic use by regulatory authorities.
Usage Guidelines
As a research compound, any guidelines regarding its use are strictly within the context of laboratory and research settings. Administration protocols and dosages vary significantly depending on the specific research objectives and animal models being used. Any information regarding human dosage or administration is speculative and not recommended.
Potential Side Effects (Based on Research)
Preclinical research on Adipotide has indicated potential side effects such as proteinuria (protein in the urine) and potential effects on kidney function. Further research is crucial to fully understand its safety profile and potential adverse effects in different biological systems.
FAQ
What is Ultima-Adiptode (FTTP)?
Ultima-Adiptode, or Prohibitin-targeting peptide 1 (FTPP), is a synthetic peptide being researched for its ability to target blood vessels in adipose tissue.
How does Adipotide work in research?
Research suggests it selectively binds to cells in the blood vessels of fat tissue, potentially leading to their death and a reduction in fat mass by limiting blood supply.
What are the potential research benefits of Adipotide?
Potential research benefits include the reduction of white adipose tissue and potential effects on body weight and metabolism in preclinical models.
What are the potential side effects observed in research?
Preclinical research has indicated potential side effects such as proteinuria and effects on kidney function.
Important Note: Ultima-Adiptode (Prohibitin-targeting peptide 1) is a research compound and is not approved for human therapeutic use by regulatory authorities. Information provided here is strictly for research and informational purposes only. It is not intended as a guide for personal use. The use of such compounds carries potential risks, and their long-term effects are not fully understood. Consult with qualified healthcare professionals for any health concerns.